Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PANFIRST** is a Sinsan Pharmaceuticals gastrointestinal prescription-product brand family rather than one chemically specific drug. Public product listings identify **PANFIRST 40** as pantoprazole 40 mg, a proton-pump inhibitor that suppresses gastric acid secretion through irreversible inhibition of the gastric H+/K+-ATPase. They identify **PANFIRST D** as a pantoprazole plus domperidone product, combining acid suppression with dopamine D2 receptor antagonism to promote upper-gastrointestinal motility and reduce nausea. The PANFIRST brand family is used for acid-related gastrointestinal conditions, including gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease; however, the exact active ingredients, dosage form, route, and mechanism depend on the named PANFIRST variant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PANFIRST.